View Item 

Show simple item record

Bacterial Overgrowth and Irritable Bowel Syndrome: Unifying Hypothesis or a Spurious Consequence of Proton Pump Inhibitors?
dc.contributor.authorSpiegel, Brennan M. R.en_US
dc.contributor.authorChey, William D.en_US
dc.contributor.authorChang, Linen_US
dc.date.accessioned2010-06-01T19:34:32Z
dc.date.available2010-06-01T19:34:32Z
dc.date.issued2008-12en_US
dc.identifier.citationSpiegel, Brennan M.R.; Chey, William D.; Chang, Lin (2008). "Bacterial Overgrowth and Irritable Bowel Syndrome: Unifying Hypothesis or a Spurious Consequence of Proton Pump Inhibitors?." The American Journal of Gastroenterology 103(12): 2972-2976. <http://hdl.handle.net/2027.42/72712>en_US
dc.identifier.issn0002-9270en_US
dc.identifier.issn1572-0241en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/72712
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=19086951&dopt=citationen_US
dc.format.extent90810 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Incen_US
dc.rights© 2008 American College of Gastroenterology/Blackwell Publishingen_US
dc.titleBacterial Overgrowth and Irritable Bowel Syndrome: Unifying Hypothesis or a Spurious Consequence of Proton Pump Inhibitors?en_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumUniversity of Michigan School of Medicine, Ann Arbor, Michiganen_US
dc.contributor.affiliationotherVA Greater Los Angeles Healthcare System, Los Angeles, Californiaen_US
dc.contributor.affiliationotherDavid Geffen School of Medicine at UCLA, Los Angeles, Californiaen_US
dc.contributor.affiliationotherCenter for Neurobiology of Stress (CNS), Los Angeles, Californiaen_US
dc.contributor.affiliationotherUCLA/VA Center for Outcomes Research and Education, Los Angeles, Californiaen_US
dc.identifier.pmid19086951en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/72712/1/j.1572-0241.2008.01992.x.pdf
dc.identifier.doi10.1111/j.1572-0241.2008.01992.xen_US
dc.identifier.sourceThe American Journal of Gastroenterologyen_US
dc.identifier.citedreferenceLongstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130: 1480 – 91.en_US
dc.identifier.citedreferenceLin HC. Small intestinal bacterial overgrowth: A framework for understanding irritable bowel syndrome. JAMA 2004; 292: 852 – 8.en_US
dc.identifier.citedreferencePimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95: 3503 – 6.en_US
dc.identifier.citedreferenceLupascu A, Gabrielli M, Lauritano EC, et al. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: A prevalence case-control study in irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22: 1157 – 60.en_US
dc.identifier.citedreferenceNucera G, Gabrielli M, Lupascu A, et al. Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth. Aliment Pharmacol Ther 2005; 1391 – 5.en_US
dc.identifier.citedreferencePimentel M, Chow EJ, Lin HC. Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome. A double-blind, randomized, placebo-controlled study. Am J Gastroenterol 2003; 98: 412 – 9.en_US
dc.identifier.citedreferencePimentel M. Help at last: The Cedars-Sinai protocol for treating IBS. In: L. Trivieri, ed. A new IBS solution. Sherman Oaks, CA: Health Point Press, 69 – 90.en_US
dc.identifier.citedreferenceSaad R, Chey WD. The role of breath tests in clinical GI practice. Gastroenterology 2007; 133: 1763 – 2007.en_US
dc.identifier.citedreferenceWalters B, Vanner SJ. Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: Comparison with 14C-D-xylose and healthy controls. Am J Gastroenterol 2005; 100: 1566 – 70.en_US
dc.identifier.citedreferencePosserud I, Stotzer PO, Bjornsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut 2007; 56: 802 – 8.en_US
dc.identifier.citedreferenceKassinen A, Krogius-Kurikka L, Makivuollo H, et al. The fecal microbiota of IBS patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24 – 33.en_US
dc.identifier.citedreferencePimentel M, Park S, Mirocha J, et al. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome. Ann Intern Med 2006; 145: 557 – 63.en_US
dc.identifier.citedreferenceDrossman D. Treatment for bacterial overgrowth in the irritable bowel syndrome. Ann Intern Med 2006; 145: 1 – 3.en_US
dc.identifier.citedreferenceDrossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125: 19 – 31.en_US
dc.identifier.citedreferenceGreene B, Blanchard EB. Cognitive therapy for irritable bowel syndrome. J Consult Clin Psychol 1994; 62: 576 – 82.en_US
dc.identifier.citedreferenceKennedy TM, Chalder T, McCrone P, et al. Cognitive behavioural therapy in addition to antispasmodic therapy for irritable bowel syndrome in primary care: Randomised controlled trial. Health Technol Assess 2006; 10: iii–iv, ix–x, 1 – 67.en_US
dc.identifier.citedreferencePayne A, Blanchard EB. A controlled comparison of cognitive therapy and self-help support groups in the treatment of irritable bowel syndrome. J Consult Clin Psychol 1995; 63: 779 – 86.en_US
dc.identifier.citedreferenceTkachuk GA, Graff LA, Martin GL, et al. Randomized controlled trial of cognitive-behavioral group therapy for irritable bowel syndrome in the medical setting. J Clin Psychol Med Settings 2003; 10: 57 – 69.en_US
dc.identifier.citedreferenceKeefer L, Blanchard EB. The effects of relaxation response meditation on the symptoms of irritable bowel syndrome: Results of a controlled treatment study. Behav Res Ther 2001; 39: 801 – 11.en_US
dc.identifier.citedreferenceLynch PM, Zamble E. A controlled behavioral treatment study of irritable bowel syndrome. Behav Ther 1989; 20: 509 – 23.en_US
dc.identifier.citedreferenceVan Der Veek PP, van Rood YR, et al. Clinical trial: Short- and long-term benefit of relaxation training for irritable bowel syndrome. Aliment Pharmacol Ther 2007; 26: 943 – 52.en_US
dc.identifier.citedreferenceBlanchard EB, Schwarz SP, Suls JM, et al. Two controlled evaluations of multicomponent psychological treatment of irritable bowel syndrome. Behav Res Ther 1992; 30: 175 – 89.en_US
dc.identifier.citedreferenceNeff DF, Blanchard EB. A multi-component treatment for irritable bowel syndrome. Behav Ther 1987; 18: 70 – 83.en_US
dc.identifier.citedreferenceShaw G, Srivastava ED, Sadlier M, et al. Stress management for irritable bowel syndrome: A controlled trial. Digestion 1991; 50: 36 – 42.en_US
dc.identifier.citedreferenceGuthrie E, Creed F, Dawson D, et al. A controlled trial of psychological treatment for the irritable bowel syndrome. Gastroenterology 1991; 100: 450 – 7.en_US
dc.identifier.citedreferenceSpiegel BMR, Naliboff B, Mayer E, et al. The effectiveness of a model physician-patient relationship versus usual care in irritable bowel syndrome: A randomized controlled trial. Gastroenterology 2006; 130: A773.en_US
dc.identifier.citedreferenceSharara AI, Aoun E, Abdul-Baki H, et al. A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 2006; 101: 326 – 33.en_US
dc.identifier.citedreferenceNastaskin I, Mehdikhani E, Conklin J, et al. Studying the overlap between IBS and GERD: A systematic review of the literature. Dig Dis Sci 2006; 51: 2113 – 20.en_US
dc.identifier.citedreferenceLocke GR, Zinsmeister AR, Fett SL, et al. Overlap of gastrointestional symptom complexes in a US community. Neurogastroenterol Motil 2005; 17: 29 – 34.en_US
dc.identifier.citedreferenceTalley NJ, Dennis EH, Schettler-Duncan VA, et al. Overlapping upper and lower gastrointestinal symptoms in irritable bowel syndrome patients with constipation or diarrhea. Am J Gastroenterol 2003; 98: 2454 – 9.en_US
dc.identifier.citedreferenceNojkov B, Saad R, Adlis S, et al. Predictors of response to PPI therapy in patients with GERD: The influence of co-morbid IBS and psychological disease. Aliment Pharmacol Ther 2008; 27: 473 – 82.en_US
dc.identifier.citedreferenceMajewski M, McCallum RW. Results of small intestinal bacterial overgrowth testing in irritable bowel syndrome patients: Clinical profiles and effects of antibiotic trial. Adv Med Sci 2007; 52: 139 – 42.en_US
dc.identifier.citedreferenceWilliams C, McColl KE. Review article: Proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006; 23: 3 – 10.en_US
dc.identifier.citedreferenceThorens J, Froehlichn F, Schwizer W, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: A prospective randomised double blind study. Gut 1996; 39: 54 – 9.en_US
dc.identifier.citedreferenceFried M, Siegrist H, Frei R, et al. Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. Gut 1994; 35: 23 – 6.en_US
dc.identifier.citedreferenceTheisen J, Nehra D, Citron D, et al. Suppression of gastric acid secretion in patients with GERD results in gastric bacterial overgrowth and deconjugation of bile acids. J Gastrointest Surg 2000; 4: 50 – 4.en_US
dc.identifier.citedreferenceLewis SJ, Franco S, Young G, et al. Altered bowel function and duodenal bacterial overgrowth in patients treated with omeprazole. Aliment Pharmacol Ther 1996; 10: 557 – 61.en_US
dc.identifier.citedreferenceLauritano E, Gabrielli M, Scarpellini E, et al. High recurrence of small intestinal bacterial overgrowth after antibiotic treatment. DDW 2007, AB S1203.en_US
dc.identifier.citedreferenceLaine L, Ahnen D, McClain C, et al. Review article: Potential GI effects of long-term acid suppression with PPIs. Aliment Pharmacol Ther 2000; 14: 651 – 68.en_US
dc.identifier.citedreferenceDial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile -associated disease. JAMA 2005; 294: 2989 – 95.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1572-0241.2008.01992.x.pdf
Size:
88.68KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.